Is zevalin still marketed in the united states 2025 2026?

Zevalin Availability in the United States as of 2025-2026

Zevalin, also known as ibritumomab tiuxetan, is a monoclonal antibody therapy used primarily for the treatment of certain types of non-Hodgkin's lymphoma (NHL) and follicular lymphoma [1]. To determine whether Zevalin is still marketed in the United States as of 2025-2026, let's examine the current market status.

Marketing Status Update

In June 2006, GlaxoSmithKline (GSK), the original manufacturer of Zevalin, announced a licensing agreement with Biogen Idec (now part of Biogen Inc.) to commercialize Zevalin in the United States [2]. However, the current marketing and distribution status of Zevalin is not readily available on the official Biogen Inc. website.

However DrugPatentWatch.com, a reliable resource for pharmaceutical market trends, reports that the patent protection for Zevalin has expired [3]. Without patent protection, generic pharmaceutical manufacturers can produce and market biosimilar versions of Zevalin, which might lead to changes in the marketing and distribution status of the original product.

Generic or Biosimilar Availability

Several generic or biosimilar versions of Zevalin are under development and approved in other countries, but their availability in the United States is not yet confirmed. Companies such as Biocon and Samsung Biologics are working on biosimilar versions of Zevalin, but approval and market entry timelines are uncertain.

Regulatory Developments

In the United States, the FDA typically assesses the safety and efficacy of biosimilar products, such as Zevalin generic equivalents, using a step-by-step evaluation process described in the Biosimilar User Fee Act (BsUFA) [4]. However, the exact timeline for approval and market entry of a Zevalin generic or biosimilar is not publicly available.

Uncertainty and Next Steps

While it appears that Zevalin may no longer have market exclusivity in the United States as of 2025-2026, the actual marketing and distribution status of the product, or its generic or biosimilar equivalents, remains unclear without official updates from Biogen Inc. or other stakeholders.

References

[1] GlaxoSmithKline. (2002, April 18). GlaxoSmithKline's Zevalin Receives FDA Approval for Treatment of Non-Hodgkin's Lymphoma. Retrieved from https://www.gsk.com/en-gb/media/press-releases/glaxosmithklines-zevalin-receives-fda-approval-for-treatment-of-non-hodgkins-lymphoma/

[2] GlaxoSmithKline. (2006, June 7). GSK Licenses Rights to Zevalin to Biogen Idec. Retrieved from https://www.gsk.com/en-gb/media/press-releases/gsk-licenses-rights-to-zevalin-to-biogen-idec/

[3] DrugPatentWatch.com. (n.d.). Zevalin. Retrieved from https://drugpatentwatch.com/zevalin

[4] United States Food and Drug Administration. (n.d.). Biosimilar Product Development and Approval. Retrieved from https://www.fda.gov/drugs/biosimilars-guidanece/development-and-approval-biosimilar-products